Supplementary Table 3 from A Phase III Clinical Trial of the Epidermal Growth Factor Vaccine CIMAvax-EGF as Switch Maintenance Therapy in Advanced Non–Small Cell Lung Cancer Patients

Abstract

<p>Related adverse events in the vaccine arm. Number of adverse events.</p>